Journal of Clinical Oncology
Articles in this Issue
Generative AI to augment the fairness of foundation models in cancer pathology diagnosis.
e23230 Background: Pathology foundation models, a type of state-of-the-art deep learning models trained on diverse and large-scale datasets, have shown th...
Clinical relevance of starting alectinib at a reduced dose in patients with ALK-positive non-small cell lung cancer.
8588 Background: Alectinib has been approved for Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) at a lower dose (300 mg twic...
Neoadjuvant lenvatinib plus pembrolizumab for resectable clear-cell renal cell carcinoma (PELUR): A prospective phase 2 study.
4541 Background: Lenvatinib plus pembrolizumab prolongs overall survival (OS) and progression-free survival (PFS) in advanced clear-cell renal cell carcin...
Efficacy and safety of BEBT-209, a primary CDK4 inhibitor, in combination with gemcitabine and carboplatin for metastatic triple-negative breast cancer.
e15144 Background: Metastatic triple-negative breast cancer (mTNBC) represents a significant unmet medical need due to the limited availability of effecti...
Survival of patients with anal adenocarcinoma in comparison to rectal adenocarcinoma: A perspective from the United States National Cancer Database.
e15504 Background: Primary adenocarcinoma of the anal canal is a rare malignancy, accounting for only 5%-10% of all anal canal cancers. Due to its aggress...
Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).
604 Background: The addition of OFS to standard endocrine therapy (ET) improves iDFS for preM women with early-stage hormone receptor positive (HR+) breas...
Real-world outcomes and toxicity profiles of bispecific antibodies: A nationwide multiyear study.
e23053 Background: The adoption of bispecific antibodies has transformed cancer therapeutics, but concerns regarding their toxicity profiles and clinical...
Exploring the role of the oral microbiome in saliva, sputum, bronchoalveolar fluid, and tissue tumor in lung cancer: A systematic review.
e20547 Background: To explore the association between the oral microbiome and the presence or progression of lung cancer (...
Global burden of multiple myeloma: Analysis from 1980 to 2021.
e19535 Background: Multiple myeloma (MM) represents approximately 10% of all hematologic malignancies. The diagnosis is established with the presence of ≥...
Phase III randomized study comparing ultra-low dose immunotherapy to standard cytotoxic chemotherapy for solid tumors in second line and beyond setting (DELII: Development of Low dose Immunotherapy in India).
2509 Background: Although immunotherapy (IO) is approved in the second line and beyond setting for most solid tumors, cost limits its accessibility. Lower...
Association of circulating tumor cells with CNS metastatic patterns and survival outcomes in HER2+ metastatic breast cancer.
e13027 Background: Central nervous system (CNS) metastases are a major complication of HER2+ metastatic breast cancer (MBC), contributing to poor prognosi...
Demographic variations, survival patterns, and mortality determinants in small-cell lung carcinoma.
e20118 Background: Small cell lung carcinoma (SCLC) accounts for 14% of all lung cancer cases and is associated with severe morbidity and mortality, parti...
A phase II exploratory study (NCT06208826) on maintenance immunotherapy in patients with resectable locally advanced head and neck cancer who achieved MPR after neoadjuvant immunotherapy combined with chemotherapy.
e18083 Background: Induction chemotherapy could improve functional preservation but could not provide long-term survival benefits in head and neck squamou...
A prospective survey of patients’ understanding on the genetic tests for cancer genetic syndromes.
e23159 Background: Genetic testing has been performed more frequently and widely in cancer patients owing to the benefits of treatment planning, prophylac...
The obesity paradox in endometrial cancer: Epidemiology of obesity among endometrial cancer patients and impact on inpatient hospitalization outcomes.
e17648 Background: Obesity is a well-established risk factor for endometrial cancer. However, its impact on clinical outcomes remains unclear (PMID: 36672...
Risk of heart failure with abiraterone versus enzalutamide amongst patients diagnosed with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
e24029 Background: Abiraterone and enzalutamide are key androgen receptor-targeted therapies for metastatic castration-resistant prostate cancer (mCRPC);...
The KRAS G12C inhibitor MK-1084 for <i>KRAS</i> G12C–mutated advanced colorectal cancer (CRC): Results from KANDLELIT-001.
3508 Background: Preliminary data from the phase 1 KANDLELIT-001 trial (NCT05067283) showed a manageable safety profile an...
Inpatient outcomes of breast cancer hospitalizations in the northeastern vs western United States.
11181 Background: Regional disparities in healthcare resources and outcomes are well-documented in the U.S., yet little is known about how they impact inp...
Experience of 25 patients treated with echoendoscopically implanted <sup>32</sup> P microparticles associated with chemotherapy in locally advanced pancreatic adenocarcinoma.
e16455 Background: Phosphorous 32 microparticle ( 32 P) brachytherapy delivered by echoendoscopy (EUS) represents an innovative th...
Variations in PSMA PET utilization, PSA testing, and urologist involvement in advanced castrate resistant prostate cancer: Comparing academic and community practices in the US.
e17075 Background: Advanced prostate cancer management has evolved with the adoption of PSMA PET imaging and refined PSA monitoring. However, real-world u...
Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).
6097 Background: For the first time weevaluated LBL-007 in combination with tislelizumab and chemotherapy in previously untreated R/M NPC in a prospective...
Early post-operative opioid fills after cancer-directed surgery among Medicare beneficiaries by race and ethnicity.
1594 Background: Post-operative pain is often underestimated and undertreated. Researchers have shown that Black patients receive fewer opioids than White...
Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses.
5502 Background: In LACC, there is an unmet need for prognostic biomarkers as about 1/3 of patients (pts) relapse after chemoradiotherapy (CRT). The globa...
The role of [18F]16α-fluoro-17β-fluoroestradiol (FES) PET in predicting response to endocrine therapy (ET) in advanced breast cancer.
e13092 Background: Seventy percent of breast cancers (BC) are estrogen receptor-positive (ER+). ET improves clinical outcomes in ER+ BC; however, ET effec...
Trends in mortality due to CNS neoplasms in the US from 1999 to 2020.
e14019 Background: CNS neoplasms are a major public health concern in the U.S., leading to substantial mortality. Despite advancements in diagnosis and tr...